Recurrent oncogenic ZC3H18 mutations stabilize endogenous retroviral RNA
Related Experiment Video
Updated: May 30, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Tanzina Tanu1, Anna M Cox1, Jennifer Karlow2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Abstract:
Endogenous retroviral (ERV) RNA is highly expressed in cancer, although the molecular causes and consequences remain unknown. We found that ZC3H18 (Z18), a component of multiple nuclear RNA surveillance complexes, has recurrent truncating mutations in cancer. We show that Z18trunc mutations are oncogenic and that Z18 plays an evolutionarily conserved role in nuclear RNA surveillance of ERV RNA. In zebrafish, Z18trunc expedited melanoma onset and promoted a specific accumulation of ERV RNA. Z18 mutant human cell lines from the Cancer Cell Line Encyclopedia also expressed higher levels of ERV RNA. In engineered human melanoma cells, Z18trunc enhanced ERV RNA accumulation more than loss of one Z18 copy, indicating dominant negative activity. Z18trunc directly bound and stabilized ERV RNA. Notably, expression of ERV RNA was sufficient to expedite oncogenesis in a zebrafish model, which is the first evidence of which we are aware that ERV transcripts can play a functional role in cancer. Our work illuminates a mechanism for elevated ERV transcripts in cancer and supports that aberrant RNA accumulation is broadly oncogenic.
Insights
Mutations in ZC3H18 (Z18) promote cancer by disrupting nuclear RNA surveillance, leading to increased endogenous retroviral (ERV) RNA accumulation. This ERV RNA accumulation accelerates cancer development, highlighting a novel oncogenic mechanism.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Endogenous retroviral (ERV) RNA is highly expressed in cancer, but its role and the underlying molecular mechanisms are unclear.
- ZC3H18 (Z18) is a nuclear RNA surveillance complex component with recurrent truncating mutations observed in cancer.
- The oncogenic potential and specific functions of Z18 mutations in cancer remain largely unknown.
Purpose of the Study:
- To investigate the role of ZC3H18 (Z18) mutations in cancer development.
- To determine the molecular mechanisms by which Z18 mutations affect endogenous retroviral (ERV) RNA levels.
- To establish whether ERV RNA accumulation can functionally contribute to oncogenesis.
Main Methods:
- Analysis of ZC3H18 (Z18) mutations in cancer patient data and cell lines.
- Functional studies in zebrafish models to assess the impact of Z18 mutations on melanoma onset and ERV RNA levels.
- In vitro experiments using engineered human melanoma cells to examine Z18's interaction with ERV RNA.
- Zebrafish oncogenesis models to test the functional role of ERV RNA expression.
Main Results:
- Recurrent truncating mutations in ZC3H18 (Z18) were identified in cancer, and these mutations were found to be oncogenic.
- Z18 mutations lead to increased accumulation of endogenous retroviral (ERV) RNA in both zebrafish and human cancer cell lines.
- Z18 mutations exhibit dominant-negative activity, directly binding and stabilizing ERV RNA.
- Expression of ERV RNA alone was sufficient to accelerate oncogenesis in a zebrafish model.
Conclusions:
- ZC3H18 (Z18) mutations disrupt nuclear RNA surveillance, causing oncogenic ERV RNA accumulation.
- Aberrant accumulation of ERV RNA is a functionally significant driver of cancer development.
- This study reveals a novel mechanism linking Z18 mutations, ERV RNA dysregulation, and oncogenesis.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Retrovirus Life Cycles
Retroviruses
Non-LTR Retrotransposons
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Viral Mutations

